Elma Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 09-12-2024
- Paid Up Capital ₹ 2.50 M
as on 09-12-2024
- Company Age 20 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.58 Cr
as on 09-12-2024
- Satisfied Charges ₹ 2.78 Cr
as on 09-12-2024
- Revenue 36.37%
(FY 2022)
- Profit -61.07%
(FY 2022)
- Ebitda 71.05%
(FY 2022)
- Net Worth 8.67%
(FY 2022)
- Total Assets 0.06%
(FY 2022)
About Elma Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹2.58 Cr. The company has closed loans amounting to ₹2.78 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nadancheri Ajith, Pallipuram Sahasranaman, Panadan Shaju, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232KL2004PTC017560
- Company No.
017560
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Oct 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Thrissur, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Elma Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pallipuram Sahasranaman  | Managing Director | 20-Jul-2006 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nadancheri Ajith | Director | 29-Oct-2004 | Current |
| Panadan Shaju | Director | 26-Oct-2007 | Current |
| Sukumar Amrutha | Director | 26-Oct-2007 | Current |
| Sajimon Abraham | Director | 01-Nov-2008 | Current |
Financial Performance of Elma Pharmaceuticals.
Elma Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 36.37% increase. The company also saw a substantial fall in profitability, with a 61.07% decrease in profit. The company's net worth moved up by a moderate rise of 8.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elma Pharmaceuticals?
In 2020, Elma Pharmaceuticals had a promoter holding of 100.00%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Munus Pharmaceuticals Private LimitedActive 8 years 29 daysNadancheri Ajith, Pallipuram Sahasranaman and 3 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Dec 2023 | ₹2.33 Cr | Open |
Others Creation Date: 27 Aug 2020 | ₹2.50 M | Open |
Others Creation Date: 11 Feb 2021 | ₹2.00 Cr | Satisfied |
How Many Employees Work at Elma Pharmaceuticals?
Elma Pharmaceuticals has a workforce of 29 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elma Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elma Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
